FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144174958> ?p ?o ?g. }

• W2144174958 endingPage "1535" @default.
• W2144174958 startingPage "1532" @default.
• W2144174958 abstract "HomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 25, No. 8Stored Iron and Vascular Reactivity Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBStored Iron and Vascular Reactivity Jerome L. Sullivan Jerome L. SullivanJerome L. Sullivan From the Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville. Search for more papers by this author Originally published1 Aug 2005https://doi.org/10.1161/01.ATV.0000174124.20147.22Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1532–1535Zheng et al1 report that volunteer blood donors with a high donation frequency have significantly greater flow-mediated dilation than low frequency donors. Iron status among the frequent donors approximated a state of iron depletion by assessment of conventional iron markers. The study provides important support for the “iron hypothesis,” which suggests a protective effect of iron depletion, ie, the absence of storage iron without anemia, against ischemic heart disease.2–4 The blood donor findings suggest a new direction for the study of endothelial iron status in vivo to complement a growing body of work on iron in cultured endothelial cells. In addition, the finding of lower serum nitrotyrosine in frequent donors is consistent with the hypothesis that myeloperoxidase, a powerful emerging cardiovascular risk factor,5–8 is modifiable by manipulation of iron status.See page 1577Endothelial Iron Status In VivoIn cultured endothelial cells, iron status can be readily manipulated through the use of iron chelators or supplemental iron,9 or by altering the essential fatty acid composition of the culture medium.10 Use of these methods has identified several important effects of iron in endothelial activation and oxidative injury.9,11–20 But the in vitro approach does not define endothelial iron status in vivo, in particular what might represent a physiologically optimal range of endothelial iron concentrations. Iron status parameters such as serum ferritin are imperfect measures of total body iron stores and are likely to be even less adequate in assessing endothelial iron status. There is the additional uncertainty of differences in storage iron concentration in various cell types, even in situations in which total body iron status is well defined.An important premise of the study by Zheng et al1 is that body iron status within the conventionally defined normal range can influence endothelial iron status and endothelial function in vivo. Alteration of endothelial function in extreme iron overload or severe iron deficiency would not be a surprise. However, there is a pervasive hidden assumption that endothelial function does not vary with iron status over a very wide but loosely defined range of “normal” stored iron concentrations. This view is related to the traditional acceptance of the safety of storage iron despite the lack of appropriate and definitive testing.21 The small but growing literature on the effects of induced iron depletion/deficiency in various experimental models of oxidative or inflammatory injury strongly supports beneficial effects of eliminating storage iron.22–40Correlation of in vitro with in vivo endothelial iron status will be assisted by future studies into the basis for an interesting phenomenon seen in human umbilical vein endothelial cells (HUVEC). Sensitivity of HUVEC to oxidative injury or high glucose levels decreases sharply with subculture in vitro after a few passages.11,13 Large increases in cellular resistance to injury correlate closely with a steep fall in cellular iron content as a function of passage number. The magnitude of the changes in iron content with subculturing is commensurate with ranges of added iron shown, for example, to markedly influence production of adhesion molecules in cultured endothelial cells.9It is not clear whether iron content in freshly harvested HUVEC, or endothelial cells from other sources for that matter, accurately reflects iron content in vivo, or, perhaps is produced as an artifact of the conditions of harvesting. If the order of magnitude greater iron content of freshly prepared cells approximates in vivo conditions, might this higher level be typical of endothelial iron status in vivo? If so, the in vitro work seems to suggest that endothelial cells could be quite sensitive to oxidative injury in vivo. However, there may be tissue specificities with respect to endothelial iron status. HUVEC are derived from umbilical vein, and as such could have endothelial iron levels higher than those encountered in other tissues at the time of harvesting because of regulatory factors involved in iron transfer from mother to fetus. Newborns, especially premature newborns, have increased susceptibility to oxidative injury. It has been proposed that this is attributable in part to features of iron metabolism in the neonatal period.41 Even term newborns typically undergo a brief period of high serum ferritin and transferrin saturation shortly after birth. Endothelial cells harvested from other tissues in adult subjects may initially have higher than optimal iron contents because of the presence of storage iron in the donor subjects favoring increased susceptibility to oxidative injury.The findings of Zheng et al1 suggest that flow-mediated dilation could be a new tool for monitoring endothelial iron status in vivo. Additional work is needed to confirm this possibility, including assessment of the effects of iron depletion on endothelium-independent vasodilation. Flow-mediated dilation may increase inversely with endothelial iron but the relationship may not be linear. Some improvement in flow-mediated dilation has been documented in patients with hemochromatosis after partial phlebotomy treatment,42 but the most prominent effects might be seen over a range of iron contents near iron deficiency. Interestingly, endothelium-independent dilation was unaffected by initial treatment in patients with hemochromatosis.42 This suggests that iron impairs flow-mediated dilation largely by modulating endothelial function.42 Serum ferritin level does not necessarily correlate well with maximal effects of iron loss near the lower end of the iron load spectrum. For example, in hepatitis C, iron reduction therapy can lower the level of serum aminotransferases. It has been reported that serum aminotransferase levels are a better guide to therapy because they continue to decrease with additional iron removal even after serum ferritin has reached its minimum value.32 Analogously, flow-mediated dilation could be a better guide than serum ferritin to achieving desired end points in endothelial iron status.Does Iron Depletion Improve Vascular Function by Decreasing Myeloperoxidase Activity?Iron depletion exerts a multitude of effects. The impact of reduced iron levels on vascular function in vivo would be expected to derive from all relevant effects in addition to changes in the concentration of iron within vascular tissue. The finding of Zheng et al1 that serum nitrotyrosine is lower in frequent blood donors is consistent with the suggestion that lowering iron levels decreases the activity of myeloperoxidase in a clinically significant manner. A significant proportion of serum nitrotyrosine appears to be derived from myeloperoxidase-dependent reactions.43–45 The emergence of myeloperoxidase as an important coronary risk factor underscores the links among iron, oxidative stress, and inflammation in cardiovascular disease. Myeloperoxidase contains iron, and its level can be lower in low iron states.23,46,47 Decreased activity of potentially injurious iron-dependent enzymes was proposed as one of a number of mechanisms by which iron depletion might protect against ischemic heart disease.3 Another example of an iron-dependent enzyme of potential importance is 5-lipoxygenase.3,48,49Diminished inflammatory injury in association with reduction in myeloperoxidase activity by induced iron deficiency was, to my knowledge, first demonstrated in 1989.23 Myeloperoxidase is thus a potentially modifiable coronary risk factor whose level may be decreased by iron removal. It is a target for intervention, not only a disease marker. Sustained iron depletion could be a feasible method for achieving stable, clinically significant myeloperoxidase reductions.Additional studies are needed to define exactly how iron depletion can lower myeloperoxidase activity and how much of a decrease in activity is achievable. Iron may be a limiting factor for myeloperoxidase formation at very low levels. It is also possible that some decrease in activity is an indirect result of a global anti-inflammatory effect of the removal of storage iron. The size of iron status-dependent differences in myeloperoxidase activity may be exaggerated in inflammatory processes. There may be significant complexities in the distribution of activity in diseased tissues, eg, within atherosclerotic lesions. The recent work of Uritski et al47 on the effects of moderate or severe iron deficiency on myeloperoxidase in an experimental model of colitis illustrates this possibility.Myeloperoxidase was recently shown to correlate inversely and highly significantly with flow-mediated dilation in human subjects.50 Flow-mediated dilation in the lowest versus the highest quartiles for serum myeloperoxidase activity were 11.1±6.0% versus 6.4±4.5%.50 The magnitude of the increase in flow-mediated dilation with frequent donation in the study of Zheng et al1 is within the same order of magnitude as the increase associated with lower myeloperoxidase activity. The magnitude of these effects suggests that an iron depletion–dependent decrease in myeloperoxidase activity could be sufficient to explain the effect of frequent blood donation.Increased Apotransferrin in Frequent DonorsIn iron deficiency, an increase in total iron binding capacity (TIBC) and a decrease in transferrin saturation are seen. These changes produce the well known increase in circulating apotransferrin concentration associated with uncomplicated iron deficiency. The high frequency donation group shows this effect to some extent even though these subjects were not anemic.1 Free transferrin is a potent antioxidant and also binds free iron. The higher level of apotransferrin in the high frequency donor group could be acting to increase dilation by a mechanism similar to that of exogenous iron chelators.51,52Iron Status In Vivo, Vascular Reactivity, and the Iron HypothesisMore than 2 decades ago, it was proposed that iron depletion protects against ischemic heart disease and that this effect may explain the remarkably low incidence of cardiovascular events in menstruating women.2,4 In the ensuing years of controversy over the validity of the idea, there have been persistent misconceptions on issues of fundamental importance.53 Zheng et al1 specifically address some of the key sources of confusion in the debate on the iron hypothesis. Iron depletion is often misconstrued to mean “a process of iron loss,” rather than the particular condition of having essentially no iron in storage but with a hemoglobin value in the normal range.This misreading of the hypothesis can result in poor study design in work on blood donation and heart disease. Casual blood donation is a process that involves iron loss, but it may have little impact on cardiovascular risk if not sufficiently regular and frequent to produce sustained iron depletion.54 Previous work on the effect of blood donation on cardiovascular disease has been inconsistent, with 3 studies supporting a protective effect55–57 and 1 negative report.58 The only study using a design similar to that of Zheng et al,1 ie, a comparison of frequent with infrequent donors,57 found lower cardiovascular disease rates in frequent donors. A design involving only donors is inherently stronger than one comparing donors with non-donors because of a lower possibility of selection bias.Future studies following up Zheng et al1 should include a prospective randomized trial of the effects of iron depletion or near iron deficiency on vascular reactivity. It is important to establish what maximum increase in flow-mediated dilation might be achievable with iron reduction therapy. The findings of Zheng et al1 do not rule out even greater increases in flow-mediated dilation in actual iron deficiency. Future studies should include direct measurement of myeloperoxidase activities and the effect of iron reduction on its level. These determinations could be helpful in assessing the relative contribution of lower myeloperoxidase activity versus change in vascular iron status to improved endothelial function. Additional epidemiological correlates that should be specifically sought in future work include the roles of stored iron acquisition as an explanation for decreased flow-mediated dilation with age59 and with the menopausal transition.60Concluding CommentA reasonable interpretation of the findings of Zheng et al1 is that reduction of stored iron level from a conventionally low level to a conventionally very low level is the factor responsible for the significant increase in flow-mediated dilation. Such an interpretation is consistent with a body of in vitro data on iron and endothelial cell function,9–20 with earlier work showing that iron chelation improves endothelial function clinically,51,52 with the improvement in flow-mediated dilation after phlebotomy treatment in hemochromatosis patients,42 and with the previously stated hypothesis on the role of iron in ischemic heart disease.2–4 However, there may be a particular impulse to interpretive caution in explaining the work of Zheng et al1 because of the persistent and widespread belief that stored iron at a conventionally normal level is entirely benign. The results of Zheng et al1 suggest that an iron-depleted subject experiences a significant decrease in flow-mediated dilation with the acquisition of essentially any stored iron. A definitive intervention study to verify that vascular function is exquisitely sensitive to the presence of stored iron should be feasible. Such a study should give valuable insight into endothelial function in vivo and could provide a new basis for evaluating the fundamental safety of storage iron.21FootnotesCorrespondence to Jerome L. Sullivan, MD, PhD, 4475 Old Bear Run, Winter Park, FL 32792. E-mail [email protected] References 1 Zheng H, Cable R, Spencer B, Votto N, Katz SD. Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol. 2005; 25: 1577–1583.LinkGoogle Scholar2 Sullivan JL. Iron and the sex difference in heart disease risk. Lancet. 1981; 1: 1293–1294.CrossrefMedlineGoogle Scholar3 Sullivan JL. The iron paradigm of ischemic heart disease. Am Heart J. 1989; 117: 1177–1188.CrossrefMedlineGoogle Scholar4 Sullivan JL. Are menstruating women protected from heart disease because of, or in spite of, estrogen? Relevance to the iron hypothesis. Am Heart J. 2003; 145: 190–194.CrossrefMedlineGoogle Scholar5 Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003; 349: 1595–1604.CrossrefMedlineGoogle Scholar6 Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003; 108: 1440–1445.LinkGoogle Scholar7 Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001; 142: 336–339.CrossrefMedlineGoogle Scholar8 Zheng L, Settle M, Brubaker G, Schmitt D, Hazen SL, Smith JD, Kinter M. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem. 2005; 280: 38–47.CrossrefMedlineGoogle Scholar9 Kartikasari AE, Georgiou NA, Visseren FL, Kats-Renaud H, van Asbeck BS, Marx JJ. Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells. Arterioscler Thromb Vasc Biol. 2004; 24: 2257–2262.LinkGoogle Scholar10 Ober MD, Hart CM. Attenuation of oxidant-mediated endothelial cell injury with docosahexaenoic acid: the role of intracellular iron. Prostaglandins, Leukotrienes and Essential Fatty Acids. 1998; 59: 127–135.CrossrefMedlineGoogle Scholar11 Varani J, Dame MK, Gibbs DF, Taylor CG, Weinberg JM, Shayevitz J, Ward PA. Human umbilical vein endothelial cell killing by activated neutrophils. Loss of sensitivity to injury is accompanied by decreased iron content during in vitro culture and is restored with exogenous iron. Lab Invest. 1992; 66: 708–714.MedlineGoogle Scholar12 Ryter SW, Si M, Lai CC, Su CY. Regulation of endothelial heme oxygenase activity during hypoxia is dependent on chelatable iron. Am J Physiol Heart Circ Physiol. 2000; 279: H2889–H2897.CrossrefMedlineGoogle Scholar13 Sasaki K, Hashida K, Michigami Y, Bannai S, Makino N. Restored vulnerability of cultured endothelial cells to high glucose by iron replenishment. Biochem Biophys Res Commun. 2001; 289: 664–669.CrossrefMedlineGoogle Scholar14 Visseren FL, Verkerk MS, van Der BT, Marx JJ, van Asbeck BS, Diepersloot RJ Iron chelation and hydroxyl radical scavenging reduce the inflammatory response of endothelial cells after infection with Chlamydia pneumoniae or influenza A. Eur J Clin Invest. 2002; 32 (Suppl 1): 84–90.Google Scholar15 Satoh T, Tokunaga O. Intracellular oxidative modification of low density lipoprotein by endothelial cells. Virchows Arch. 2002; 440: 410–417.CrossrefMedlineGoogle Scholar16 Zhang WJ, Frei B. Intracellular metal ion chelators inhibit TNFalpha-induced SP-1 activation and adhesion molecule expression in human aortic endothelial cells. Free Radic Biol Med. 2003; 34: 674–682.CrossrefMedlineGoogle Scholar17 Koo SW, Casper KA, Otto KB, Gira AK, Swerlick RA. Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J Invest Dermatol. 2003; 120: 871–879.CrossrefMedlineGoogle Scholar18 Ramachandran A, Ceaser E, Darley-Usmar VM. Chronic exposure to nitric oxide alters the free iron pool in endothelial cells: role of mitochondrial respiratory complexes and heat shock proteins. Proc Natl Acad Sci U S A. 2004; 101: 384–389.CrossrefMedlineGoogle Scholar19 Soares MP, Seldon MP, Gregoire IP, Vassilevskaia T, Berberat PO, Yu J, Tsui TY, Bach FH. Heme Oxygenase-1 modulates the expression of adhesion molecules associated with endothelial cell activation. J Immunol. 2004; 172: 3553–3563.CrossrefMedlineGoogle Scholar20 Dhanasekaran A, Kotamraju S, Kalivendi SV, Matsunaga T, Shang T, Keszler A, Joseph J, Kalyanaraman B. Supplementation of endothelial cells with mitochondria-targeted antioxidants inhibit peroxide-induced mitochondrial iron uptake, oxidative damage, and apoptosis. J Biol Chem. 2004; 279: 37575–37587.CrossrefMedlineGoogle Scholar21 Sullivan J. Is stored iron safe? J Lab Clin Med. 2004; 144: 280–284.CrossrefMedlineGoogle Scholar22 Sullivan JL, Till GO, Ward PA. Iron depletion decreases lung injury after systemic complement activation. Fed Proc. 1986; 45: 452.Google Scholar23 Sullivan JL, Till GO, Ward PA, Newton RB. Nutritional iron restriction diminishes acute complement-dependent lung injury. Nutrition Research. 1989; 9: 625–634.CrossrefGoogle Scholar24 Andrews FJ, Morris CJ, Lewis EJ, Blake DR. Effect of nutritional iron deficiency on acute and chronic inflammation. Ann Rheum Dis. 1987; 46: 859–865.CrossrefMedlineGoogle Scholar25 Chandler DB, Barton JC, Briggs DD III, Butler TW, Kennedy JI, Grizzle WE, Fulmer JD. Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. Am Rev Respir Dis. 1988; 137: 85–89.CrossrefMedlineGoogle Scholar26 Patt A, Horesh IR, Berger EM, Harken AH, Repine JE. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. J Pediatr Surg. 1990; 25: 224–227.CrossrefMedlineGoogle Scholar27 Salonen JT, Korpela H, Nyyssonen K, Porkkala E, Tuomainen TP, Belcher JD, Jacobs DR, Jr., Salonen R. Lowering of body iron stores by blood letting and oxidation resistance of serum lipoproteins: a randomized cross-over trial in male smokers. J Intern Med. 1995; 237: 161–168.CrossrefMedlineGoogle Scholar28 Lee TS, Shiao MS, Pan CC, Chau LY. Iron-deficient diet reduces atherosclerotic lesions in apoE-deficient mice. Circulation. 1999; 99: 1222–1229.CrossrefMedlineGoogle Scholar29 Lee HT, Chiu LL, Lee TS, Tsai HL, Chau LY. Dietary iron restriction increases plaque stability in apolipoprotein-e-deficient mice. J Biomed Sci. 2003; 10: 510–517.CrossrefMedlineGoogle Scholar30 van Jaarsveld H, Pool GF. Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis. 2002; 161: 395–402.CrossrefMedlineGoogle Scholar31 Yoshiji H, Nakae D, Mizumoto Y, Horiguchi K, Tamura K, Denda A, Tsujii T, Konishi Y. Inhibitory effect of dietary iron deficiency on inductions of putative preneoplastic lesions as well as 8-hydroxydeoxyguanosine in DNA and lipid peroxidation in the livers of rats caused by exposure to a choline-deficient L-amino acid defined diet. Carcinogenesis. 1992; 13: 1227–1233.CrossrefMedlineGoogle Scholar32 Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol. 1995; 22: 268–271.CrossrefMedlineGoogle Scholar33 Ponraj D, Makjanic J, Thong PS, Tan BK, Watt F. The onset of atherosclerotic lesion formation in hypercholesterolemic rabbits is delayed by iron depletion. FEBS Lett. 1999; 459: 218–222.CrossrefMedlineGoogle Scholar34 Facchini FS. Near-iron deficiency-induced remission of gouty arthritis. Rheumatology (Oxford). 2003; 42: 1–6.CrossrefGoogle Scholar35 Facchini FS, Saylor KL. Effect of iron depletion on cardiovascular risk factors: studies in carbohydrate-intolerant patients. Ann N Y Acad Sci. 2002; 967: 342–351.MedlineGoogle Scholar36 Facchini FS, Saylor KL. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes. 2003; 52: 1204–1209.CrossrefMedlineGoogle Scholar37 DePalma RG, Hayes VW, Cafferata HT, Mohammadpour HA, Chow BK, Zacharski LR, Hall MR. Cytokine signatures in atherosclerotic claudicants. J Surg Res. 2003; 111: 215–221.CrossrefMedlineGoogle Scholar38 Park YY, Hybertson BM, Wright RM, Repine JE. Serum ferritin increases in hemorrhaged rats that develop acute lung injury: effect of an iron-deficient diet. Inflammation. 2003; 27: 257–263.CrossrefMedlineGoogle Scholar39 Shoham S, Youdim MBH. Nutritional iron deprivation attenuates kainate-induced neurotoxicity in rats: implications for involvement of iron in neurodegeneration. Ann N Y Acad Sci. 2004; 1012: 94–114.CrossrefMedlineGoogle Scholar40 Barollo M, D’Inca R, Scarpa M, Medici V, Cardin R, Fries W, Angriman I, Sturniolo GC. Effects of iron deprivation or chelation on DNA damage in experimental colitis. Int J Colorectal Dis. 2004; 19: 461–466.CrossrefMedlineGoogle Scholar41 Sullivan JL. Iron, plasma antioxidants, and the ‘oxygen radical disease of prematurity.’ Am J Dis Child. 1988; 142: 1341–1344.MedlineGoogle Scholar42 Gaenzer H, Marschang P, Sturm W, Neumayr G, Vogel W, Patsch J, Weiss G. Association between increased iron stores and impaired endothelial function in patients with hereditary hemochromatosis. J Am Coll of Cardiol. 2002; 40: 2189–2194.CrossrefMedlineGoogle Scholar43 Hurst JK. Whence nitrotyrosine? J Clin Invest. 2002; 109: 1287–1289.CrossrefMedlineGoogle Scholar44 Brennan ML, Wu W, Fu X, Shen Z, Song W, Frost H, Vadseth C, Narine L, Lenkiewicz E, Borchers MT, Lusis AJ, Lee JJ, Lee NA, Abu-Soud HM, Ischiropoulos H, Hazen SL. A tale of two controversies: i) Defining the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase deficient mice; and ii) Defining the nature of peroxidase-generated reactive nitrogen species. J Biol Chem. 2002; 277: 17415–17427.CrossrefMedlineGoogle Scholar45 Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White CR, Bullard DC, Brennan ML, Lusis AJ, Moore KP, Freeman BA. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001; 108: 1759–1770.CrossrefMedlineGoogle Scholar46 Murakawa H, Bland CE, Willis WT, Dallman PR. Iron deficiency and neutrophil function: different rates of correction of the depressions in oxidative burst and myeloperoxidase activity after iron treatment. Blood. 1987; 69: 1464–1468.CrossrefMedlineGoogle Scholar47 Uritski R, Barshack I, Bilkis I, Ghebremeskel K, Reifen R. Dietary iron affects inflammatory status in a rat model of colitis. J Nutr. 2004; 134: 2251–2255.CrossrefMedlineGoogle Scholar48 Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, Funk CD, Lusis AJ, Shih W. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res. 2002; 91: 120–126.LinkGoogle Scholar49 Zhang YY, Lind B, Radmark O, Samuelsson B. Iron content of human 5-lipoxygenase, effects of mutations regarding conserved histidine residues. J Biol Chem. 1993; 268: 2535–2541.CrossrefMedlineGoogle Scholar50 Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, Hazen SL. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004; 110: 1134–1139.LinkGoogle Scholar51 Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, Vita JA. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001; 103: 2799–2804.CrossrefMedlineGoogle Scholar52 Zheng H, Dimayuga C, Hudaihed A, Katz SD. Effect of dexrazoxane on homocysteine-induced endothelial dysfunction in normal subjects. Arterioscler Thromb Vasc Biol. 2002; 22: e15–e18.LinkGoogle Scholar53 Sullivan JL. Misconceptions in the debate on the iron hypothesis. J Nutr Biochem. 2001; 12: 33–37.CrossrefMedlineGoogle Scholar54 Kiechl S, Willeit J. Ongoing controversies surrounding the vascular benefits of blood donation. Circulation. 2001; 104: E99.LinkGoogle Scholar55 Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol. 1998; 148: 445–451.CrossrefMedlineGoogle Scholar56 Meyers DG, Strickland D, Maloley PA, Seburg JK, Wilson JE, McManus BF. Possible association of a reduction in cardiovascular events with blood donation. Heart. 1997; 78: 188–193.CrossrefMedlineGoogle Scholar57 Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. Transfusion. 2002; 42: 1135–1139.CrossrefMedlineGoogle Scholar58 Ascherio A, Rimm EB, Giovannucci E, Willett WC, Stampfer MJ. Blood donations and risk of coronary heart disease in men. Circulation. 2001; 103: 52–57.CrossrefMedlineGoogle Scholar59 Ahlers BA, Parnell MM, Chin-Dusting JP, Kaye DM. An age-related decline in endothelial function is not associated with alterations in L-arginine transport in humans. J Hypertens. 2004; 22: 321–327.CrossrefMedlineGoogle Scholar60 Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation. 1998; 97: 1234–1238.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Quintana Pacheco D, Sookthai D, Wittenbecher C, Graf M, Schübel R, Johnson T, Katzke V, Jakszyn P, Kaaks R and Kühn T (2018) Red meat consumption and risk of cardiovascular diseases—is increased iron load a possible link?, The American Journal of Clinical Nutrition, 10.1093/ajcn/nqx014, 107:1, (113-119), Online publication date: 1-Jan-2018. Pisano G, Lombardi R and Fracanzani A (2016) Vascular Damage in Patients with Nonalcoholic Fatty Liver Disease: Possible Role of Iron and Ferritin, International Journal of Molecular Sciences, 10.3390/ijms17050675, 17:5, (675) Fernández-Real J and Manco M (2014) Effects of iron overload on chronic metabolic diseases, The Lancet Diabetes & Endocrinology, 10.1016/S2213-8587(13)70174-8, 2:6, (513-526), Online publication date: 1-Jun-2014. Hunnicutt J, He K and Xun P (2014) Dietary Iron Intake and Body Iron Stores Are Associated with Risk of Coronary Heart Disease in a Meta-Analysis of Prospective Cohort Studies, The Journal of Nutrition, 10.3945/jn.113.185124, 144:3, (359-366), Online publication date: 1-Mar-2014. Holsworth R, Cho Y, Weidman J, Sloop G and Cyr J (2013) Cardiovascular benefits of phlebotomy: relationship to changes in hemorheological variables, Perfusion, 10.1177/0267659113505637, 29:2, (102-116), Online publication date: 1-Mar-2014. Mainous A, Wright R, Hulihan M, Twal W, McLaren C, Diaz V, McLaren G, Argraves W and Grant A (2013) Elevated transferrin saturation, health-related quality of life and telomere length, BioMetals, 10.1007/s10534-013-9693-4, 27:1, (135-141), Online publication date: 1-Feb-2014. Mascitelli L and Goldstein M (2013) Vascular beneficial effects of polyphenol-rich olive oil and reduced body iron stores, European Journal of Nutrition, 10.1007/s00394-013-0611-x, 52:8, (1961-1962), Online publication date: 1-Dec-2013. Cable R, Glynn S, Kiss J, Mast A, Steele W, Murphy E, Wright D, Sacher R, Gottschall J, Tobler L and Simon T (2011) Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study, Transfusion, 10.1111/j.1537-2995.2011.03401.x, 52:4, (702-711), Online publication date: 1-Apr-2012. Rajapurkar M, Shah S, Lele S, Hegde U, Lensing S, Gohel K, Mukhopadhyay B, Gang S and Eigenbrodt M (2012) Association of Catalytic Iron With Cardiovascular Disease, The American Journal of Cardiology, 10.1016/j.amjcard.2011.09.032, 109:3, (438-442), Online publication date: 1-Feb-2012. Singh B, Arora S, Agrawal P and Gupta S (2011) Hepcidin: A novel peptide hormone regulating iron metabolism, Clinica Chimica Acta, 10.1016/j.cca.2011.02.014, 412:11-12, (823-830), Online publication date: 1-May-2011. Brittenham G (2011) Iron deficiency in whole blood donors, Transfusion, 10.1111/j.1537-2995.2011.03062.x, 51:3, (458-461), Online publication date: 1-Mar-2011. Cable R, Glynn S, Kiss J, Mast A, Steele W, Murphy E, Wright D, Sacher R, Gottschall J, Vij V and Simon T (2010) Iron deficiency in blood donors: analysis of enrollment data from the REDS-II Donor Iron Status Evaluation (RISE) study, Transfusion, 10.1111/j.1537-2995.2010.02865.x, 51:3, (511-522), Online publication date: 1-Mar-2011. Kell D (2009) Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases, BMC Medical Genomics, 10.1186/1755-8794-2-2, 2:1, Online publication date: 1-Dec-2009. Sullivan J (2009) Do Hemochromatosis Mutations Protect Against Iron-Mediated Atherogenesis?, Circulation: Cardiovascular Genetics, 2:6, (652-657), Online publication date: 1-Dec-2009. Sullivan J (2009) Iron in arterial plaque: A modifiable risk factor for atherosclerosis, Biochimica et Biophysica Acta (BBA) - General Subjects, 10.1016/j.bbagen.2008.06.005, 1790:7, (718-723), Online publication date: 1-Jul-2009. Li L and Frei B (2009) Prolonged Exposure to LPS Increases Iron, Heme, and p22phox Levels and NADPH Oxidase Activity in Human Aortic Endothelial Cells, Arteriosclerosis, Thrombosis, and Vascular Biology, 29:5, (732-738), Online publication date: 1-May-2009. Dwyer B, Zacharski L, Balestra D, Lerner A, Perry G, Zhu X and Smith M (2009) Getting the iron out: Phlebotomy for Alzheimer’s disease?, Medical Hypotheses, 10.1016/j.mehy.2008.12.029, 72:5, (504-509), Online publication date: 1-May-2009. Ibrahim H, Foley R, Zhang R, Gilbertson D and Collins A (2009) Parenteral Iron Use: Possible Contribution to Exceeding Target Hemoglobin in Hemodialysis Patients, Clinical Journal of the American Society of Nephrology, 10.2215/CJN.03850808, 4:3, (623-629), Online publication date: 1-Mar-2009. Sullivan J (2016) Macrophage Iron, Hepcidin, and Atherosclerotic Plaque Stability, Experimental Biology and Medicine, 10.3181/0703-MR-54, 232:8, (1014-1020), Online publication date: 1-Sep-2007. Sullivan J (2016) The Big Idea: the coxib crisis Iron, aspirin and heart disease risk revisited, Journal of the Royal Society of Medicine, 10.1177/014107680710000721, 100:7, (346-349), Online publication date: 1-Jul-2007. Li L and Frei B (2006) Iron Chelation Inhibits NF-κB–Mediated Adhesion Molecule Expression by Inhibiting p22phox Protein Expression and NADPH Oxidase Activity, Arteriosclerosis, Thrombosis, and Vascular Biology, 26:12, (2638-2643), Online publication date: 1-Dec-2006. Carraway M, Suliman H, Madden M, Piantadosi C and Ghio A (2006) Metabolic capacity regulates iron homeostasis in endothelial cells, Free Radical Biology and Medicine, 10.1016/j.freeradbiomed.2006.09.005, 41:11, (1662-1669), Online publication date: 1-Dec-2006. Lee D, Zacharski L and Jacobs D (2006) Comparison of the serum ferritin and percentage of transferrin saturation as exposure markers of iron-driven oxidative stress–related disease outcomes, American Heart Journal, 10.1016/j.ahj.2006.03.009, 151:6, (1247.e1-1247.e7), Online publication date: 1-Jun-2006. Stone N (2006) Therapy and clinical trials, Current Opinion in Lipidology, 10.1097/01.mol.0000217904.90315.29, 17:2, (199-201), Online publication date: 1-Apr-2006. Kartikasari A, Georgiou N, Visseren F, van Kats‐Renaud H, van Asbeck B and Marx J (2005) Endothelial activation and induction of monocyte adhesion by nontransferrin‐bound iron present in human sera, The FASEB Journal, 10.1096/fj.05-4700fje, 20:2, (353-355), Online publication date: 1-Feb-2006. Sullivan J (2006) Is homocysteine an iron-dependent cardiovascular risk factor?, Kidney International, 10.1038/sj.ki.5000229, 69:4, (642-644), Online publication date: 1-Feb-2006. Mascitelli L, Pezzetta F and Sullivan J (2006) Iron Chelation by Green Tea Flavonoids and Improved Endothelial Function in Chronic Smokers, Circulation Journal, 10.1253/circj.70.1523, 70:11, (1523-1524), . Drüeke T and Massy Z (2005) Intravenous Iron: How Much Is Too Much?, Journal of the American Society of Nephrology, 10.1681/ASN.2005080804, 16:10, (2833-2835), Online publication date: 1-Oct-2005. August 2005Vol 25, Issue 8 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.0000174124.20147.22PMID: 16055755 Originally publishedAugust 1, 2005 Keywordsendotheliummyeloperoxidasegenetics of cardiovascular diseaseoxidant stressironPDF download Advertisement" @default.
• W2144174958 created "2016-06-24" @default.
• W2144174958 creator A5047924930 @default.
• W2144174958 date "2005-08-01" @default.
• W2144174958 modified "2023-10-16" @default.
• W2144174958 title "Stored Iron and Vascular Reactivity" @default.
• W2144174958 cites W1508323668 @default.
• W2144174958 cites W1598210890 @default.
• W2144174958 cites W1599213425 @default.
• W2144174958 cites W161242125 @default.
• W2144174958 cites W1969699149 @default.
• W2144174958 cites W1971584572 @default.
• W2144174958 cites W1977745350 @default.
• W2144174958 cites W1980459953 @default.
• W2144174958 cites W1988375247 @default.
• W2144174958 cites W1995282389 @default.
• W2144174958 cites W2001752044 @default.
• W2144174958 cites W2005107018 @default.
• W2144174958 cites W2012920582 @default.
• W2144174958 cites W2013253392 @default.
• W2144174958 cites W2014520319 @default.
• W2144174958 cites W2018769683 @default.
• W2144174958 cites W2024497094 @default.
• W2144174958 cites W2029824307 @default.
• W2144174958 cites W2041930667 @default.
• W2144174958 cites W2047525244 @default.
• W2144174958 cites W2050846920 @default.
• W2144174958 cites W2052667261 @default.
• W2144174958 cites W2056325568 @default.
• W2144174958 cites W2060348573 @default.
• W2144174958 cites W2066635679 @default.
• W2144174958 cites W2066747037 @default.
• W2144174958 cites W2070858375 @default.
• W2144174958 cites W2077120170 @default.
• W2144174958 cites W2083007412 @default.
• W2144174958 cites W2091693528 @default.
• W2144174958 cites W2094934523 @default.
• W2144174958 cites W2104420627 @default.
• W2144174958 cites W2108014410 @default.
• W2144174958 cites W2114490800 @default.
• W2144174958 cites W2115723679 @default.
• W2144174958 cites W2116073940 @default.
• W2144174958 cites W2116835524 @default.
• W2144174958 cites W2124042160 @default.
• W2144174958 cites W2125064850 @default.
• W2144174958 cites W2125990672 @default.
• W2144174958 cites W2137930965 @default.
• W2144174958 cites W2141409038 @default.
• W2144174958 cites W2156196043 @default.
• W2144174958 cites W2158862170 @default.
• W2144174958 cites W2161040303 @default.
• W2144174958 cites W2165322433 @default.
• W2144174958 cites W2174804674 @default.
• W2144174958 cites W2401070909 @default.
• W2144174958 cites W4232550118 @default.
• W2144174958 cites W4240381454 @default.
• W2144174958 cites W1999512844 @default.
• W2144174958 doi "https://doi.org/10.1161/01.atv.0000174124.20147.22" @default.
• W2144174958 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16055755" @default.
• W2144174958 hasPublicationYear "2005" @default.
• W2144174958 type Work @default.
• W2144174958 sameAs 2144174958 @default.
• W2144174958 citedByCount "38" @default.
• W2144174958 countsByYear W21441749582012 @default.
• W2144174958 countsByYear W21441749582013 @default.
• W2144174958 countsByYear W21441749582014 @default.
• W2144174958 countsByYear W21441749582015 @default.
• W2144174958 countsByYear W21441749582016 @default.
• W2144174958 countsByYear W21441749582018 @default.
• W2144174958 countsByYear W21441749582021 @default.
• W2144174958 crossrefType "journal-article" @default.
• W2144174958 hasAuthorship W2144174958A5047924930 @default.
• W2144174958 hasBestOaLocation W21441749581 @default.
• W2144174958 hasConcept C142724271 @default.
• W2144174958 hasConcept C185592680 @default.
• W2144174958 hasConcept C204787440 @default.
• W2144174958 hasConcept C2776910235 @default.
• W2144174958 hasConcept C71924100 @default.
• W2144174958 hasConceptScore W2144174958C142724271 @default.
• W2144174958 hasConceptScore W2144174958C185592680 @default.
• W2144174958 hasConceptScore W2144174958C204787440 @default.
• W2144174958 hasConceptScore W2144174958C2776910235 @default.
• W2144174958 hasConceptScore W2144174958C71924100 @default.
• W2144174958 hasIssue "8" @default.
• W2144174958 hasLocation W21441749581 @default.
• W2144174958 hasLocation W21441749582 @default.
• W2144174958 hasLocation W21441749583 @default.
• W2144174958 hasOpenAccess W2144174958 @default.
• W2144174958 hasPrimaryLocation W21441749581 @default.
• W2144174958 hasRelatedWork W1976253167 @default.
• W2144174958 hasRelatedWork W2009996801 @default.
• W2144174958 hasRelatedWork W2397218192 @default.
• W2144174958 hasRelatedWork W2399033717 @default.
• W2144174958 hasRelatedWork W2402690918 @default.
• W2144174958 hasRelatedWork W2801688792 @default.
• W2144174958 hasRelatedWork W2949852058 @default.
• W2144174958 hasRelatedWork W2950013228 @default.
• W2144174958 hasRelatedWork W2951808849 @default.

• next